Related Experiment Videos
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
1Department of Radiation Oncology, Stanford University, California 94305.
British Journal of Cancer
|June 1, 1993
Summary
Tirapazamine, a novel bioreductive anticancer drug, selectively kills tumor cells with low oxygen levels (hypoxia). This drug enhances radiotherapy efficacy by targeting resistant hypoxic cells without increasing normal tissue toxicity.
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Solid tumors contain hypoxic cells resistant to conventional therapies.
- SR 4233 (tirapazamine) is a novel benzotriazine di-N-oxide bioreductive drug.
- Hypoxia-selective agents are needed to overcome treatment resistance.
Purpose of the Study:
- To review the development and potential of tirapazamine as a hypoxia-targeted anticancer agent.
- To discuss tirapazamine's mechanism of action and efficacy in preclinical and clinical studies.
- To highlight tirapazamine's role as an adjunct to radiotherapy and chemotherapy.
Main Methods:
- Review of preclinical and clinical data on SR 4233 (tirapazamine).
- Analysis of tirapazamine's cytotoxicity as a function of oxygen concentration.
- Examination of in vivo evidence for its use with radiotherapy and chemotherapy.
Main Results:
- Tirapazamine exhibits potent cytotoxicity specifically under hypoxic conditions.
- It selectively targets and kills hypoxic tumor cells, which are resistant to other treatments.
- Combination therapy with tirapazamine and fractionated irradiation significantly increases tumor cell killing without augmenting normal tissue toxicity.
Conclusions:
- Tirapazamine represents a promising new class of bioreductive anticancer drugs targeting tumor hypoxia.
- Its ability to enhance radiotherapy suggests significant potential as an adjuvant cancer therapy.
- Further research is needed to address outstanding questions regarding its clinical application.